radalbuvir radalbuvir radalbuvir (inn, also known as gs-9669) is an experimental antiviral drug for the treatment of hepatitis c virus (hcv) infection developed by gilead sciences. radalbuvir acts as an ns5b inhibitor. it is currently in clinical trials. it targets ns5b polymerase. radalbuvirclinical dataother namesgs-9669legal statuslegal status us: investigational new drug identifiers iupac name 5-(3,3-dimethylbut-1-yn-1-yl)-3-methyl)cyclohexyl]-4-methylcyclohex-3-ene-1-carboxamido}thiophene-2-carboxylic acid cas number1314795-11-3pubchem cid53259022chemspider31140180unii273k4v0spcchemical and physical dataformulac30h41no6smolar mass543.72 g·mol−13d model (jsmol)interactive image smiles cc1=cc(cc1)c(=o)n(2cc(cc2)(o)co3cocc3)c4c(sc(c4)c#cc(c)(c)c)c(=o)o inchi inchi=1s/c30h41no6s/c1-20-5-7-21(8-6-20)27(32)31(25-17-24(11-13-29(2,3)4)38-26(25)28(33)34)22-9-14-30(35,15-10-22)19-37-23-12-16-36-18-23/h5,17,21-23,35h,6-10,12,14-16,18-19h2,1-4h3,(h,33,34)/t21-,22-,23-,30+/m0/s1key:muicupwicxunrs-gdccixdysa-n